Venketasubramanian Narayanaswamy, Kumar Ramesh, Soertidewi Lyna, Abu Bakar Azizi, Laik Carine, Gan Robert
Department of Neurology, Raffles Neuroscience Centre, Raffles Hospital, Singapore, Singapore.
Department of Neurosurgery, Faculty of Medicine, University Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.
BMJ Open. 2015 Nov 13;5(11):e009866. doi: 10.1136/bmjopen-2015-009866.
NeuroAiD (MLC601, MLC901), a combination of natural products, has been shown to be safe and to aid neurological recovery after brain injuries. The NeuroAiD Safe Treatment (NeST) Registry aims to assess its use and safety in the real-world setting.
The NeST Registry is designed as a product registry that would provide information on the use and safety of NeuroAiD in clinical practice. An online NeST Registry was set up to allow easy entry and retrieval of essential information including demographics, medical conditions, clinical assessments of neurological, functional and cognitive state, compliance, concomitant medications, and side effects, if any, among patients on NeuroAiD. Patients who are taking or have been prescribed NeuroAiD may be included. Participation is voluntary. Data collected are similar to information obtained during standard care and are prospectively entered by the participating physicians at baseline (before initialisation of NeuroAiD) and during subsequent visits. The primary outcome assessed is safety (ie, non-serious and serious adverse event), while compliance and neurological status over time are secondary outcomes. The in-person follow-up assessments are timed with clinical appointments. Anonymised data will be extracted and collectively analysed. Initial target sample size for the registry is 2000. Analysis will be performed after every 500 participants entered with completed follow-up information.
Doctors who prescribe NeuroAiD will be introduced to the registry by local partners. The central coordinator of the registry will discuss the protocol and requirements for implementation with doctors who show interest. Currently, the registry has been approved by the Ethics Committees of Universiti Kebangsaan Malaysia (Malaysia) and National Brain Center (Indonesia). In addition, for other countries, Ethics Committee approval will be obtained in accordance with local requirements.
NCT02536079.
NeuroAiD(MLC601、MLC901)是一种天然产物的组合,已被证明安全且有助于脑损伤后的神经恢复。NeuroAiD安全治疗(NeST)注册研究旨在评估其在现实环境中的使用情况和安全性。
NeST注册研究设计为一个产品注册研究,将提供NeuroAiD在临床实践中的使用和安全性信息。设立了一个在线NeST注册平台,以便轻松录入和检索重要信息,包括人口统计学信息、医疗状况、神经、功能和认知状态的临床评估、依从性、合并用药以及服用NeuroAiD患者的副作用(如有)。正在服用或已被开具NeuroAiD处方的患者可被纳入。参与是自愿的。收集的数据与标准护理期间获得的信息相似,由参与的医生在基线(NeuroAiD初始化前)和后续随访时前瞻性录入。评估的主要结局是安全性(即非严重和严重不良事件),而依从性和随时间的神经状态是次要结局。面对面随访评估与临床预约时间同步。将提取匿名数据并进行汇总分析。该注册研究的初始目标样本量为2000。每有500名录入完整随访信息的参与者后将进行分析。
开具NeuroAiD处方的医生将由当地合作伙伴介绍参与该注册研究。注册研究的中央协调员将与感兴趣的医生讨论实施方案和要求。目前,该注册研究已获得马来西亚国立大学(马来西亚)和国家脑中心(印度尼西亚)伦理委员会的批准。此外,对于其他国家,将根据当地要求获得伦理委员会的批准。
NCT02536079。